These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30008270)

  • 1. Determinants of viral load rebound on HIV/AIDS patients receiving antiretroviral therapy: results from South Africa.
    Shoko C; Chikobvu D
    Theor Biol Med Model; 2018 Jul; 15(1):10. PubMed ID: 30008270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
    Shoko C; Chikobvu D; Bessong PO
    S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling of viral load dynamics and CD4 cell count progression in an antiretroviral naive cohort: using a joint linear mixed and multistate Markov model.
    Dessie ZG; Zewotir T; Mwambi H; North D
    BMC Infect Dis; 2020 Mar; 20(1):246. PubMed ID: 32216755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
    Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
    Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Blasco AJ; Llibre JM; Berenguer J; González-García J; Knobel H; Lozano F; Podzamczer D; Pulido F; Rivero A; Tuset M; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2015 Mar; 33(3):156-65. PubMed ID: 25175171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling immune deterioration, immune recovery and state-specific duration of HIV-infected women with viral load adjustment: using parametric multistate model.
    Dessie ZG; Zewotir T; Mwambi H; North D
    BMC Public Health; 2020 Mar; 20(1):416. PubMed ID: 32228523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Antiretroviral Therapy on CD4+ Cell Count, HIV Viral Load and Death in a South African Cohort: A Modelling Study.
    Shoko C; Chikobvu D; Bessong PO
    Pak J Biol Sci; 2020 Mar; 23(4):542-551. PubMed ID: 32363840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-state Markov model for time to treatment changes for HIV/AIDS patients: a retrospective cohort national datasets, Ethiopia.
    Kumsa TH; Mulu A; Beyene J; Asfaw ZG
    BMC Infect Dis; 2024 Jun; 24(1):627. PubMed ID: 38914968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.
    McColl DJ; Margot N; Chen SS; Harris J; Borroto-Esoda K; Miller MD
    HIV Clin Trials; 2011; 12(2):61-70. PubMed ID: 21498149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-homogeneous Markov process for HIV/AIDS progression under a combination treatment therapy: cohort study, South Africa.
    Shoko C; Chikobvu D
    Theor Biol Med Model; 2018 Jan; 15(1):3. PubMed ID: 29343268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.